Volume 26, Number 12—December 2020
Dispatch
Hypervirulent Klebsiella pneumoniae as Unexpected Cause of Fatal Outbreak in Captive Marmosets, Brazil
Juliana Mariotti Guerra, Natália Coelho Couto de A. Fernandes, Alessandra Loureiro Morales dos Santos, Joana de Souza Pereira Barrel, Bruno Simões Sergio Petri, Liliane Milanelo, Monique Ribeiro Tiba-Casas, Alcina Maria Liserre, Cláudia Regina Gonçalves, Cláudio Tavares Sacchi, José Luiz Catão-Dias, and Carlos Henrique Camargo
Table 2
Antimicrobial susceptibility profile of highly virulent Klebsiella pneumoniae sequence type 86 strain P04 from a fatal epizootic among captive marmosets in Brazil, 2019*
| Antimicrobial | MIC, mg/L† | Category |
|---|---|---|
| Amikacin | <4.0 | Susceptible |
| Ampicillin/sulbactam | 8/4 | Susceptible |
| Aztreonam | <2 | Susceptible |
| Cefepime | <2 | Susceptible |
| Cefotaxime | <2 | Susceptible |
| Ceftazidime | <1.0 | Susceptible |
| Ciprofloxacin | <0.06 | Susceptible |
| Colistin | <0.25 | Susceptible |
| Doripenem | <0.5 | Susceptible |
| Doxycycline | 2.0 | Susceptible |
| Gentamicin | <1.0 | Susceptible |
| Imipenem | <1.0 | Susceptible |
| Levofloxacin | <1.0 | Susceptible |
| Meropenem | <1.0 | Susceptible |
| Minocycline | 4.0 | Susceptible |
| Piperacillin/tazobactam | <8/4 | Susceptible |
| Polymyxin B | <0.25 | Susceptible |
| Sulfamethoxazole/trimethoprim | <0.5/9.5 | Susceptible |
| Ticarcillin/clavulanic Acid | <16/2 | Susceptible |
| Tigecycline‡ | 0.5 | Susceptible |
| Tobramycin | <1.0 | Susceptible |
*Susceptibility determined by Sensititre (ThermoFisher, https://www.thermofisher.com). †MIC values were categorized as susceptible, intermediate, or resistance following Clinical and Laboratory Standards Institute (https://clsi.org) M100-S30 breakpoints (http://em100.edaptivedocs.net/dashboard.aspx). ‡Tigecycline breakpoint followed Food and Drug Administration recommendations.
Page created: October 13, 2020
Page updated: November 19, 2020
Page reviewed: November 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.